nach oben

Drugs

Erschienen in:

01.03.2014 | R&D Insight Report

Umeclidinium/Vilanterol: First Global Approval

verfasst von: Lesley J. Scott, Philip Hair

Erschienen in: Drugs | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Umeclidinium/vilanterol (Anoro™ Ellipta™ [USA; Canada; proposed Japan]; Anoro™ [proposed EU]), an inhaled fixed-dose combination of a long-acting muscarinic antagonist and a long-acting β₂-adrenergic agonist, is indicated for once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Umeclidinium/vilanterol received its first global approval in this indication in the USA and has subsequently been approved for use in the same indication in Canada, with submissions for regulatory approval in patients with COPD under review elsewhere, including in Europe and Japan. This article summarizes the milestones in the development of umeclidinium/vilanterol leading to its first approval for maintenance treatment of airflow obstruction in patients with COPD.

Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013. http://www.goldcopd.org/. Accessed 9 Jan 2014.

Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Resp Crit Care Med. 2013;187(4):347–65.PubMedCrossRef

US Food and Drug Administration. FDA approves Anoro Ellipta to treat chronic obstructive pulmonary disease. 2013. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm379057.htm. Accessed 10 Jan 2014.

GlaxoSmithKline Inc. Anoro Ellipta approved for COPD in Canada [media release]. 2014. http://www.firstwordpharma.com/node/1177487?tsid=28&region_id=3#axzz2qDDGAfxx. Accessed 13 Jan 2014.

Theravance Inc, GlaxoSmithKline plc. GlaxoSmithKline to increase its shareholding in Theravance [media release]. 2010. http://www.gsk.com/media/press-releases/2010/glaxosmithkline-to-increase-its-shareholding-in-theravance.html. Accessed 9 Jan 2014.

GlaxoSmithKline plc, Theravance Inc. GSK and Theravance announce regulatory submission for Anoro™ Ellipta™ (UMEC/VI) in Japan [media release]. 2013. http://www.gsk.com/media/press-releases/2013/gsk-and-theravance-announce-regulatory-submission-for-anoro-elli.html. Accessed 10 Jan 2014.

GlaxoSmithKline. Anoro Ellipta (umeclidinium and vilanterol) inhalation powder: USA prescribing information. 2014. http://www.rxlist.com/anoro-ellipta-drug.htm. Accessed 9 Jan 2014.

GlaxoSmithKline. A multicenter, trial comparing the efficacy and safety of umeclidinium/vilanterol 62.5/25 μg once daily with tiotropium 18 μg once daily over 24 weeks in subjects with chronic obstructive pulmonary disease (COPD) [ClinicalTrials.gov identifier NCT01777334]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 20 Dec 2013.

GlaxoSmithKline. A 52 week study to evaluate the safety and tolerability of GSK573719/GW642444 125 μg once-daily alone and in combination with GW642444 25 μg once-daily via novel dry powder inhaler (nDPI) in Japanese subjects with chronic obstructive pulmonary disease [ClinicalTrials.gov identifier NCT01376388]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 12 Dec 2013.

10.

Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological characterization of GSK57319 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic receptors for treatment of pulmonary disease. J Pharmacol Exp Ther. 2013;345(2):260–70.PubMedCrossRef

11.

Slack RJ, Barrett VJ, Morrison VS, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β₂-adreneroreceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013;344(1):218–30.PubMedCrossRef

12.

Kelleher D, Tombs L, Crater G, et al. A placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects [abstract]. AmJ Respir Crit Care Med. 2013;187:A1487.

13.

Goyal N, Beerahee M, Kalberg C, et al. Population pharmacokinetics of umeclidinium and vilanterol in patients with COPD [abstract no. 1708416]. Clin Pharmacol Drug Dev. 2013;2(Suppl. 1):28.

14.

Kelleher DL, Mehta RS, Jean-Francois BM, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. PLoS ONE. 2012;7(12):e50716.PubMedCentralPubMedCrossRef

15.

Mehta R, Hardes K, Kelleher D, et al. Effect of moderate hepatic impairment (MHI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) [abstract no. P3641]. In: 23rd Annual congress of the European Respiratory Society, Barcelona, 7–11 Sep 2013.

16.

Kelleher D, Hardes K, Brealey N, et al. Effect of severe renal impairment (SRI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) [abstract no. P4148]. In: 23rd Annual congress of the European Respiratory Society, Barcelona, 7–11 Sep 2013.

17.

Mehta R, Kelleher D, Preece A, et al. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study. Int J COPD. 2013;8:159–67.CrossRef

18.

Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25mcg inCOPD. Respir Med. 2013;107(10):1538–46.PubMedCrossRef

19.

Celli BR, Crater G, Kilbride S, et al. A 24-week randomized, double-blind, placebo-controlled study of the efficacy and safety of once-daily umeclidinium/vilanterol 125/25 mcg in COPD [abstract]. Am J Respir Crit Care Med. 2013;187:A2435.

20.

GlaxoSmithKline. Pulmonary Allergy Drugs Advisory Committee Meeting: FDA briefing document. NDA 203-975: umeclidinium and vilanterol inhalation powder for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). 2013. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pulmonary-allergydrugsadvisorycommittee/ucm367411.pdf. Accessed 10 Jan 2014.

21.

Anzueto A, Decramer M, Kaelin T, et al. The efficacy and safety of umeclidinium/vilanterol compared with tiotropium or vilanterol over 24 weeks in subjects with COPD [abstract]. Am J Respir Crit Care Med. 2013;187:A4268.

22.

GlaxoSmithKline. DB2113374: a multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GSK573719 and with tiotropium over 24 weeks in subjects with chronic obstructive pulmonary disease (COPD) [ClinicalTrials.gov identifier NCT01316913]. US National Institutes of Health, ClinicalTrials.gov 2013. http://www.clinicaltrials.gov. Accessed 20 Dec 2013.

23.

Maltais F, Singh S, Donald A, et al. Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: two randomised clinical trials [abstract no. P761]. In: 23rd Annual congress of the European Respiratory Society, Barcelona, 7–11 Sep 2013.

24.

Riley J, Tabberer M, Richard N, et al. Use of a new dry powder inhaler to deliver umeclidinium/vilanterol in the treatment of COPD [abstract no. P4145]. In: 23rd Annual congress of the European Respiratory Society, Barcelona, 7–11 Sep 2013.

25.

Donohue J, Niewoehner D, Brooks J, et al. Long-term safety and tolerability of umeclidinium/vilanterol and umeclidinium in COPD [abstract no. P760]. In: 23rd Annual congress of the European Respiratory Society, Barcelona, 7–11 Sep 2013.

Titel: Umeclidinium/Vilanterol: First Global Approval
verfasst von: Lesley J. Scott
Philip Hair
Publikationsdatum: 01.03.2014
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 3/2014
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-014-0186-8

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Erratum to: T-Cell Trafficking and Anti-Adhesion Strategies in Inflammatory Bowel Disease: Current and Future Prospects

Drug Treatment of Hypertension in Pregnancy

Prevention of Postoperative Recurrence in Crohn’s Disease

Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus

Colistimethate Sodium Dry Powder for Inhalation: A Review of Its Use in the Treatment of Chronic Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis

Erratum to: Oxycodone/Naloxone Prolonged-Release: A Review of Its Use in the Management of Chronic Pain While Counteracting Opioid-Induced Constipation